NCT01749150 - A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Hepatitis C, Chronic

Interventions

DRUG

danoprevir + ritonavir

125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks

DRUG

danoprevir + ritonavir

125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 mcg sc weekly, 12 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 mcg sc weekly, 24 weeks

DRUG

ribavirin [Copegus]

1000-1200 mg orally daily in divided doses, 12 weeks

DRUG

ribavirin [Copegus]

1000-1200 mg orally daily in divided doses, 24 weeks

Trial Locations (13)

100

Taipei

333

Taoyuan District

640

Yunlin County

807

Kaohsiung City

10330

Bangkok

10700

Bangkok

40447

Taichung

50200

Chiang Mai

61363

Chiayi County

614-735

Busan

110-744

Seoul

120-752

Seoul

135-710

Seoul

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY